吉非替尼联合DC-CIK细胞治疗晚期肺腺癌的临床疗效观察  

Effects of gefitinib combined with DC-CIK on advanced lung adenocarcinoma

作　　者：胡作为[1] 赵霞[1] 关江锋[1] 宋文玲[2] 曾辉[2] 

机构地区：[1]武汉市第一医院肿瘤生物治疗中心,武汉430022 [2]武汉市黄陂区人民医院暨江汉大学附属第三医院肿瘤三科,武汉432200

出　　处：《中国医师杂志》2016年第1期56-59,62,共5页Journal of Chinese Physician

基　　金：湖北省自然科学基金项目（ZRY2014001530）

摘　　要：目的 评价吉非替尼联合树突状细胞（DC）-细胞因子激活的杀伤细胞（CIK）即DC-CIK细胞治疗晚期肺腺癌的近期疗效和不良反应.方法 50例经放疗和一线化疗后的晚期肺腺癌患者接受吉非替尼联合DC-CIK细胞治疗,观察治疗前后血常规变化、影像学资料、癌胚抗原及生活质量变化.结果 治疗后患者部分缓解（PR） 24例,稳定（SD） 17例,进展（PD）9例;近期有效率（RR）48％,患者生活质量明显改善.常见不良反应为皮疹、腹泻、低热和寒战,但症状轻微,对症治疗后均缓解.DC-CIK可有效缓解肺癌患者化疗后骨髓抑制反应,使WBC的数目明显升高（P＜0.01）;治疗后肿瘤患者外周血CEA含量明显降低（P＜0.01）.治疗后患者LCSS和KPS评分明显优于治疗前（P＜0.05）.结论 吉非替尼联合自体DC-CIK细胞输注二线治疗晚期肺腺癌安全,无明显不良反应,近期有一定的疗效.吉非替尼联合自体DC-CIK细胞治疗能明显改善晚期肺癌患者的骨髓抑制,提高患者生活质量,且安全可靠.远期疗效有待于进一步观察.Objective To investigate the short-term efficacy and safety of gefitinib combined with dendritic cells-cytokine induced killer （DC-CIK） cells in the treatment of advanced lung adenocarcinoma.Methods Fifty patients with lung adenocarcinoma who in previous had underwent radiotherapy and first-line chemotherapy failure received DC-CIK in combination with gefitinib treatment,blood count changes,imaging data,carcinoembryonic antigen and changes in the quality of life before and after treatment were compared and evaluated.Results DC-CIK could improve effectively and relieve bone marrow suppression response after chemotherapy and significantly increase the WBC content of blood （P 〈 0.01）.After treatment,the tumor carcinoembryonic antigen （CEA） was significantly lower in patients （P 〈 0.01）.Fifty cases of patients in complete remission （CR） were 0 cases,partial remission （PR） were 24 cases,stable disease （SD） were 17 cases and progression （PD） were 9 cases,and the response rates （RR） were 48%;The quality of life of patients was significantly improved （P 〈 0.05）.Common adverse reactions were rash,diarrhea,chill and fever,but mild symptoms could be relieved after symptomatic treatment.Conclusions Gefitinib with autologous DC-CIK cell infusion second-line treatment of advanced lung cancer have a certain short-term efficacy,without significant adverse reactions.Gefitinib with autologous DC-CIK cell therapy can mitigate the response of bone marrow suppression in patients with advanced lung cancer and improve the quality of life of patients.Long-term effect remains to be investigated.

关 键 词：喹唑啉类/投药和剂量 树突细胞 杀伤细胞 肺肿瘤/治疗 

分 类 号：R734.2[医药卫生—肿瘤]